International Journal of Trichology最新文献_第8页

Halting the Progression of Cicatricial Alopecia with Injectable Platelet-Rich Fibrin. 用注射富血小板纤维蛋白阻止角化性脱发的发展

International Journal of Trichology Pub Date : 2023-07-01 Epub Date: 2024-04-05 DOI: 10.4103/ijt.ijt_116_21

Siddhi Bhalchandra Chikhalkar, Surender Singh, Avani Jatin Kumar Shah, Bhushan Madke, Yallappa Ramchandrappa Kabbannavar

引用次数: 0

Photodistributed Lichenoid Eruption with Alopecia: A Unique Presentation of Graham-Little-Piccardi-Lasseur Syndrome. 伴有脱发的光分布性苔藓样变：格雷厄姆-利特尔-皮卡迪-拉瑟尔综合征的独特表现

International Journal of Trichology Pub Date : 2023-07-01 Epub Date: 2024-04-05 DOI: 10.4103/ijt.ijt_47_22

Austin Ambur, Aashni Bhukhan, Charles Dunn, Rajiv Nathoo

引用次数: 0

Meta-analysis on the Efficacy of Platelet-rich Plasma in Patients with Androgenetic Alopecia. 富血小板血浆对雄激素性脱发患者疗效的 Meta 分析。

International Journal of Trichology Pub Date : 2023-07-01 Epub Date: 2024-04-05 DOI: 10.4103/ijt.ijt_90_22

Olga Olisova, Mariia Potapova, Aleksandr Suvorov, Danila Koriakin, Anfisa Lepekhova

引用次数: 0

Nivolumab-Induced Lichen Planopilaris: Case Report and Literature Review of Hair Disorders Associated with Targeted Oncological Therapies. Nivolumab诱发的扁平苔藓：肿瘤靶向治疗相关毛发疾病的病例报告和文献综述。

International Journal of Trichology Pub Date : 2023-05-01 Epub Date: 2023-12-01 DOI: 10.4103/ijt.ijt_95_21

Leila Asfour, David Rutkowski, Iskander H Chaudhry, Matthew J Harries

{"title":"Nivolumab-Induced Lichen Planopilaris: Case Report and Literature Review of Hair Disorders Associated with Targeted Oncological Therapies.","authors":"Leila Asfour, David Rutkowski, Iskander H Chaudhry, Matthew J Harries","doi":"10.4103/ijt.ijt_95_21","DOIUrl":"10.4103/ijt.ijt_95_21","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapies. Their mechanism promotes a cytotoxic T-cell activation against the tumor cells, but as a consequence, immune-mediated toxicities are increasingly being identified. Cutaneous immune-mediated adverse events (AE) occur in 32% of patients, with possible higher grade AEs seen with anti-programmed cell death protein 1, such as nivolumab. A 67-year-old woman with metastatic melanoma, previously treated for 2 years on dual ICI (ipilimumab and nivolumab), had her treatment interrupted due to grade-3 hepatitis. She was subsequently recommenced on single-agent nivolumab with good response, before discontinuation due to remission. She reported worsening scalp pruritus with associated erythema, scaling, and global hair thinning. On examination, she had significant erythema throughout the scalp with perifollicular scaling and evidence of scarring. She reported severe distress from her symptoms. Her scalp biopsy demonstrated features of scarring alopecia with infundibular and isthmic inflammation and interface change in keeping with lichen planopilaris. Follicular toxicities are rarely reported, possibly due to imprecise AE phenotyping or underreporting. However, growing evidence suggests that patients can develop follicular pigmentary changes and nonscarring alopecia. To our knowledge, this is the first case of scarring alopecia reported with nivolumab. Current treatments for ICI-induced toxicities are limited.","PeriodicalId":14417,"journal":{"name":"International Journal of Trichology","volume":"15 3","pages":"105-107"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Comment on Mercantilism in the Trichological Sciences. 对毛细管科学中的重商主义的评论。

International Journal of Trichology Pub Date : 2023-05-01 Epub Date: 2023-12-01 DOI: 10.4103/ijt.ijt_29_21

Ralph Michel Trüeb

{"title":"A Comment on Mercantilism in the Trichological Sciences.","authors":"Ralph Michel Trüeb","doi":"10.4103/ijt.ijt_29_21","DOIUrl":"10.4103/ijt.ijt_29_21","url":null,"abstract":"A quasi-scientific interest in hair loss and hair care originated in a London barbershop, and became known as trichology, with the Institute of Trichologists being founded. Other corporations successively followed, offering paid courses by home-study for training of initiates who desire more knowledge about hair. Trichologists are not medically qualified but are taught the practice of care and treatment of the hair and scalp in health and disease within their restricted but specialized role. With the advent of opportunities in the social media, and of epiluminiscence microscopy, a procedure practiced by the guild of trichologists long before its nominal introduction as trichoscopy into dermatologic practice, representatives of the medical profession are following the example of the trichologists in offering online courses, though with a better understanding of clinical-pathological correlations based on their academic learning. Despite the enthusiasm emerging with its establishment as a dermatologic tool in the diagnosis of hair and scalp disorders, caution is warranted not to elevate trichoscopy to something like a fetish status. As a diagnostic procedure, trichoscopy is to be understood as representing an integral part of a comprehensive dermatological examination. The Hippocratic Oath is one of the oldest binding documents in history, allegedly still held sacred by physicians: to treat the ill to the best of one's ability, to preserve a patient's privacy, and to teach the secrets of medicine to the next generation without fee. And yet, as in no other field of medicine, paid online courses on trichoscopy are flourishing and with a primary commercial aim. However, dermato-trichology, or trichiatry require the same due diligence as any other medical discipline, with respect to its practice and its ethics. Medical artistry is neither reducible to a single hand-held diagnostic technique nor is it negotiable.","PeriodicalId":14417,"journal":{"name":"International Journal of Trichology","volume":"15 3","pages":"85-87"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comment on Topical Dapsone for Folliculitis Decalvans. 关于外用多潘松治疗德卡尔瓦毛囊炎的评论

International Journal of Trichology Pub Date : 2023-05-01 Epub Date: 2023-12-01 DOI: 10.4103/ijt.ijt_39_22

Ralph Michel Trüeb, Ngoc-Nhi Catharina Luu, Hudson Dutra Rezende

{"title":"Comment on Topical Dapsone for Folliculitis Decalvans.","authors":"Ralph Michel Trüeb, Ngoc-Nhi Catharina Luu, Hudson Dutra Rezende","doi":"10.4103/ijt.ijt_39_22","DOIUrl":"10.4103/ijt.ijt_39_22","url":null,"abstract":"Folliculitis decalvans (FD) represents a chronic and recurrent pustulofollicular scalp inflammation resulting in scarring alopecia. The presence of a bacterial bioflilm at the interface of the hair shaft may provide an explanation for the chronicity and high relapse rate of FD, even after prolonged systemic antibiotic treatments. We originally read with enthusiasm Melián-Olivera et al.'s retrospective study of patients with FD treated with topical dapsone published in the Journal of the American Academy of Dermatology. However, we experienced an unsuccessful trial of 5% dapsone gel in a patient with FD resulting in worsening of the disease with a pustular flareup and questioned why positive study reports with novel therapeutic options in dermatology often fail in practice. The authors admitted the limitations of their study: small sample size, retrospective, uncontrolled nature of the study, and concomitant use of other treatments. Clinical research ultimately aims at improving the patient outcome. For this purpose, trials must evaluate the outcomes that genuinely reflect the clinical utility of drugs. Therefore, we postulate stricter criteria for treatment trials and statistics in dermatology before publication in peer-reviewed scientific journals to avoid frustrations of physicians and patients alike.","PeriodicalId":14417,"journal":{"name":"International Journal of Trichology","volume":"15 3","pages":"88-90"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tofacitinib: A Promising Treatment for Adolescent Alopecia Areata. 托法替尼托法替尼：治疗青少年斑秃的有效方法。

International Journal of Trichology Pub Date : 2023-05-01 Epub Date: 2023-12-01 DOI: 10.4103/ijt.ijt_90_23

Nitika Wagh

引用次数: 0

A Promising Efficacy of Tofacitinib in an Adult Patient with Alopecia Areata. 托法替尼对成人脱发患者的疗效令人鼓舞

International Journal of Trichology Pub Date : 2023-05-01 Epub Date: 2023-12-01 DOI: 10.4103/ijt.ijt_91_23

Amit Bharat Shah

引用次数: 0

Efficacy, Tolerability, and Superiority of Propylene Glycol-Free, North American Witch-Hazel (Hamamelis virginiana)-Based Solution of 5% Minoxidil Sulfate for the Treatment of Female Androgenetic Alopecia. 不含丙二醇、基于北美金缕梅（Hamelis virginiana）的 5%硫酸米诺地尔溶液治疗女性雄激素性脱发症的疗效、耐受性和优越性。

International Journal of Trichology Pub Date : 2023-05-01 Epub Date: 2023-12-01 DOI: 10.4103/ijt.ijt_55_22

Ralph Michel Trüeb

{"title":"Efficacy, Tolerability, and Superiority of Propylene Glycol-Free, North American Witch-Hazel (Hamamelis virginiana)-Based Solution of 5% Minoxidil Sulfate for the Treatment of Female Androgenetic Alopecia.","authors":"Ralph Michel Trüeb","doi":"10.4103/ijt.ijt_55_22","DOIUrl":"10.4103/ijt.ijt_55_22","url":null,"abstract":"Background: Androgenetic alopecia leads to progressive hair loss in susceptible individuals if left untreated. Topical minoxidil represents an evidence-based treatment for female androgenetic alopecia, though with variable success.Aims and objectives: Treatment of minoxidil non-responders remains challenging, as does treatment of patients with propylene glycol sensitivity or irritable scalp syndrome.Materials and methods: Single-center, retrospective cohort of 50 female patients with androgenetic alopecia failing to respond to a minimum of 6 months of standard 5% topical minoxidil solution either once daily or b.i.d. depending on the severity of the alopecia. Patients were switched to propylene glycol-free, North American Witch Hazel (Hamamelis virginiana)-based solution of 5% minoxidil sulfate (5% minoxidil sensitive solution). Efficacy and safety of treatment were evaluated, including stereotactic global photography and epiluminiscence microscopy with digital imaging taken at baseline, at 3, and at 6 months of treatment.Results: 70% of patients showed observable clinical improvement with combined global photographic and epiluminiscence microscopic assessment with digital imaging, and 22% epiluminiscence microscopic-only improvement as evidence of treatment efficacy. The treatment was well tolerated, particularly in patients with propylene glycol sensitivity and patients with irritable scalp syndrome.Conclusions: These results suggest that propylene glycol-free, North American witch hazel (Hamamelis virginiana)-based solution of 5% minoxidil is effective and safe for treatment of female androgenetic alopecia, specifically in minoxidil non-responders and patients with propylene glycol sensitivity or irritable scalp syndrome.","PeriodicalId":14417,"journal":{"name":"International Journal of Trichology","volume":"15 3","pages":"108-112"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Low-dose Oral Minoxidil in the Treatment of Alopecia: Evidence and Experience-based Consensus Statement of Indian Experts. 治疗脱发的低剂量米诺地尔口服液：印度专家基于证据和经验的共识声明》。

International Journal of Trichology Pub Date : 2023-05-01 Epub Date: 2023-12-01 DOI: 10.4103/ijt.ijt_70_23

Kiran Godse, Abhishek De, Maya Vedamurthy, D S Krupa Shankar, Bela Shah, Mukesh Girdhar, Ramesh Bhat, Anil Ganjoo, Sushil Tahiliani, Anant Patil

{"title":"Low-dose Oral Minoxidil in the Treatment of Alopecia: Evidence and Experience-based Consensus Statement of Indian Experts.","authors":"Kiran Godse, Abhishek De, Maya Vedamurthy, D S Krupa Shankar, Bela Shah, Mukesh Girdhar, Ramesh Bhat, Anil Ganjoo, Sushil Tahiliani, Anant Patil","doi":"10.4103/ijt.ijt_70_23","DOIUrl":"10.4103/ijt.ijt_70_23","url":null,"abstract":"Alopecia is a highly prevalent condition worldwide including in India. There are different types of alopecia with differing etiology, presentation, and hence treatment. Androgenetic alopecia represents the most common form of hair loss affecting male as well as female population termed as male and female pattern hair loss, respectively. Several treatment options are available for the treatment of alopecia with often unsatisfactory results resulting in psychological distress among such patients. Topical minoxidil is known to be effective in the treatment of alopecia. However, oral minoxidil is not currently approved for the treatment of alopecia. This expert consensus is prepared to provide guidance to the clinicians regarding the use of oral minoxidil in the treatment of alopecia. Extensive literature review was performed to prepare the draft consensus which was then revised based on the suggestions and comments from the experts. The final draft was circulated to the experts for review and approval. This consensus document provides overview of evidence related to oral minoxidil and consensus from the experts for its use in the treatment of minoxidil.","PeriodicalId":14417,"journal":{"name":"International Journal of Trichology","volume":"15 3","pages":"91-97"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0